About PSM
Partnership for Safe Medicines urges FDA advisory committee to reject compounding of unapproved peptides
On July 23-24, the FDA will evaluate seven peptides for custom pharmacy compounding. Citing a critical deficit in human safety data, widespread consumer confusion, and systemic supply chain vulnerabilities, PSM urges the committee to block mass compounding and protect patient safety.
[...]June 29, 2026: PSM releases road map to improve patient safety amidst compounding boom
A Call to Action: Restoring and Strengthening America’s Patient Safety System presents a two pillar system for regulators and lawmakers to preserve the FDAs gold standard.
[...]Joint statement on warning to pharmacists about diverted HIV medicines being sold on online pharmacy-to-pharmacy platforms
ADAP Advocacy and the Partnership for Safe Medicines (PSM) issued the following joint statement as a warning to pharmacists that all discounted HIV products bought from online, pharmacy-to-pharmacy (P2P) marketplaces fit the definition of suspect product under U.S. Food and Drug Administration (FDA) guidelines and the Drug Supply Chain Security Act.
[...]Peptide therapies — popular, unproven, dangerous
Americans have become accustomed to taking peptides for for improved health, but unless they’ve undergone clinical trials and received FDA approval, there’s no way to establish a peptide’s safety or effectiveness.
[...]Weight loss promotions are out of hand on social media, and it’s endangering patients
The internet is overrun with content promoting injectable weight loss medicines and there’s no way for viewers to know whether what they’re seeing is legitimate, genuine, safe, or true. Policymakers, social media platforms, and individuals can make changes to protect the public in this dangerous advertising environment.
[...]A Call to Action: Restoring and strengthening America’s patient safety system; protecting patients from the risks of mass drug compounding
PMS’s new report outlines solutions to protect patient safety in the growing compounded GLP-1 marketplace. A Call to Action: Restoring and Strengthening America’s Patient Safety System serves as a roadmap for policymakers and regulators to uphold the gold standard system that protects Americans from untested and unsafe medicines.
[...]Partnership for Safe Medicines releases action plan to protect patients from unapproved compounded GLP-1s
PMS’s new report outlines solutions to protect patient safety in the growing compounded GLP-1 marketplace. A Call to Action: Restoring and Strengthening America’s Patient Safety System serves as a roadmap for policymakers and regulators to uphold the gold standard system that protects Americans from untested and unsafe medicines.
[...]Prescription Drug Freight Fraud, June 2026 report
March and April 2026 saw thousands of shipments of drugs imported into the US, including weight loss drugs and antibiotics. We studied these shipments to learn more about their manufacturers and contents.
[...]Partnership for Safe Medicines Applauds FDA Action to Curb Unsafe Compounding of GLP-1 Medications
The Partnership for Safe Medicines strongly supports the Food and Drug Administration’s proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list. This action reflects sound science, sound law, and a clear-eyed commitment to patient safety. Full statement inside.
[...]Prescription Drug Freight Fraud Report, April 2026
What do FDA records of GLP-1 and antibiotic imports show about freight fraud patterns over the last six months?
[...]